Clinical characteristics of the patient cohort with data shown for the entire patient group, as well as separately for HLA-DRB1*03 positive and negative patients
| All patients | HLA-DRB1*03 positive patients | HLA-DRB1*03 negative patients | |
| Patients n | 43 | 26 | 17 |
| Sex | |||
| Male | 27 | 15 | 12 |
| Female | 16 | 11 | 5 |
| Age years | 39.0 (33.0–49.5) | 36.0 (32.3–43.8) | 45.0 (33.0–63.0) |
| Löfgren's syndrome n | 26 | 22 | 4 |
| Chest radiographic stage# | |||
| 0 | 0 | 0 | 0 |
| I | 26 | 21 | 5 |
| II | 14 | 5 | 9 |
| III | 2 | 0 | 2 |
| IV | 1 | 0 | 1 |
| Smoking status | |||
| Non-smoker | 21 | 13 | 8 |
| Former smoker | 15 | 8 | 7 |
| Current smoker | 7 | 5 | 2 |
| VC % pred | 85.0 (79.0–95.0) | 85.0 (80.0–97.0) | 84.5 (75.8–92.8) |
| FEV1 % pred | 87.0 (77.0–99.0) | 91.5 (85.8–99.3) | 76.0 (69.0–84.5) |
| DLCO % pred | 86.0 (73.0–95.0) | 87.0 (77.0–97.5) | 84.0 (74.3–92.0) |
| BAL recovery % | 64.0 (58.5–71.0) | 67.5 (62.3–71.8) | 60.0 (52.0–69.0) |
| BAL cell concentration¶ 106 cells·L−1 | 212.6 (116.7–321.3) | 183.4 (129.3–300.8) | 279.4 (108.8–364.9) |
| Macrophages % | 73.6 (56.2–85.7) | 75.7 (64.1–88.3) | 66.3 (49.2–79.6) |
| Lymphocytes % | 25.0 (12.2–40.4) | 19.2 (10.2–32.1) | 32.0 (18.6–49.0) |
| Neutrophils % | 1.4 (0.7–2.2) | 1.6 (0.7–2.3) | 1.3 (0.8–1.6) |
| Eosinophils % | 0.2 (0.0–0.6) | 0.1 (0.0–0.6) | 0.2 (0.0–0.6) |
| BAL CD4/CD8 ratio | 9.2 (5.3–17.5) | 12.9 (6.3–20.7) | 7.2 (3.6–12.0) |
Data are presented as median (interquartile range), unless otherwise stated. VC: vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; BAL: bronchoalveolar lavage. #: chest radiography staging as follows: stage 0: normal chest radiography; stage I: enlarged lymph nodes; stage II: enlarged lymph nodes with parenchymal infiltrates; stage III: parenchymal infiltrates without enlarged lymph nodes; and stage IV signs of pulmonary fibrosis. ¶: BAL basophils and mast cells were excluded from the cell differential counts.